Lou Gehrig's Disease Pipeline Landscape Report 2024: Therapeutic Assessment of 80+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks [Yahoo! Finance]
ExeVir Announces Michael Garrett as New Chief Executive Officer [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]